Theravance Biopharma (TBPH) Change in Acquisitions & Divestments (2014 - 2026)

Theravance Biopharma (TBPH) has reported Change in Acquisitions & Divestments for 13 consecutive years, with $96.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 194.48% year-over-year to $96.0 million; the TTM figure through Mar 2026 stood at $206.4 million (up 60.74% YoY), while the FY2025 annual figure was $143.0 million, up 2.26% from the prior year.
• Change in Acquisitions & Divestments rose to $96.0 million in Q1 2026 per TBPH's latest filing, from $65.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $96.0 million in Q1 2026 and bottomed at -$108.7 million in Q4 2022.
• Historically, Change in Acquisitions & Divestments has averaged $25.6 million across 5 years, with a median of $30.4 million in 2024.
• Annual changes were most pronounced in 2022 — Change in Acquisitions & Divestments tumbled 267.72% — and 2024, when it surged 226.06%.
• Theravance Biopharma's Change in Acquisitions & Divestments stood at -$108.7 million in 2022, then jumped by 63.25% to -$39.9 million in 2023, then surged by 200.27% to $40.1 million in 2024, then surged by 63.6% to $65.5 million in 2025, then jumped by 46.51% to $96.0 million in 2026.
• Business Quant data shows TBPH's Change in Acquisitions & Divestments at $96.0 million in Q1 2026, $65.5 million in Q4 2025, and $24.5 million in Q3 2025.